At a glance
ClinicalIndex Comparison Record- ✓Diagnosed moderate-to-severe obstructive sleep apnea with apnea hypopnea index >15 events/hr
- ✕Cardiovascular disease other than well controlled hypertension
- ✕Depression
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effect of Desipramine on Upper Airway Collapsibility and Genioglossus Muscle Activity During Sleep in Patients With Obstructive Sleep Apnea - Study B
In Brief
A Phase 2 clinical trial evaluating Desipramine and Placebo for Sleep Apnea, Obstructive. Completed, enrolled 16 participants across 1 site.
Detailed Summary
Obstructive sleep apnea (OSA) is common and has major health implications but treatment options are limited. OSA patients show a marked reduction in upper airway (UA) dilator muscle activity at sleep onset and this phenomenon leads to increased collapsibility of UA compared to normal participants. Until recently, the search for medicines to activate pharyngeal muscles in sleeping humans has been discouraging. However, exciting new animal research has shown that drugs with noradrenergic and antimuscarinic effects can restore pharyngeal muscle activity to waking levels. In this protocol the investigators will test the effect of desipramine (a tricyclic antidepressant with strong noradrenergic and antimuscarinic effects) on upper airway collapsibility and genioglossus muscle activity (EMG GG) during sleep in OSA patients.
Study Details
Timeline
Interventions
200 mg administered 2 hours before normal sleep time
Placebo-matching desipramine administered 2 hours before normal sleep time